[{"orgOrder":0,"company":"Cell Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Duolac7S","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cell Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cell Biotech Co., Ltd \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Cell Biotech Co., Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Duolac7S is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Irritable Bowel Syndrome.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 18, 2010

                          Lead Product(s) : Duolac7S

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank